What is UroGen Pharma's total equity?

UroGen Pharma (URGN) reported total equity of -$124.25M in Q1 2026.

How has UroGen Pharma's total equity changed year-over-year?

UroGen Pharma's total equity decreased by 167.5% year-over-year, from -$46.46M to -$124.25M.

What is the long-term trend for UroGen Pharma's total equity?

Over 5 years (2020 to 2025), UroGen Pharma's total equity has grown at a 1.8% compound annual growth rate (CAGR), from $96.36M to -$105.47M.

What does total equity mean?

Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

UroGen Pharma URGN Total Equity

Total Equity at other companies

Bristol-Myers SquibbBMY

$20.07B+15.4%

PfizerPFE

$90.1B-0.3%

Merck & Co.MRK

$45.88B-5.1%

ImmunityBio, Inc.IBRX

-$870.01M-47.1%

Tyra Biosciences, Inc.TYRA

$387.58M+19.8%

Johnson & JohnsonJNJ

——

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.71B+71.7%

Enterprise value$1.8B+80.9%

P/S12.2×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's total equity?: UroGen Pharma (URGN) reported total equity of -$124.25M in Q1 2026.
How has UroGen Pharma's total equity changed year-over-year?: UroGen Pharma's total equity decreased by 167.5% year-over-year, from -$46.46M to -$124.25M.
What is the long-term trend for UroGen Pharma's total equity?: Over 5 years (2020 to 2025), UroGen Pharma's total equity has grown at a 1.8% compound annual growth rate (CAGR), from $96.36M to -$105.47M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.